Besides the molecular pathway, the fact that DMF is the first approved Nrf2-inducer in clinic and is used for the treatment of multiple sclerosis demonstrates the importance of this factor for promoting myelination. The gene discussed is NFE2L2; the disease is multiple sclerosis.